BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29600973)

  • 1. Signatures of anti-Thomsen - Friedenreich antigen antibody diversity in colon cancer patients.
    Kurtenkov O; Bubina M; Klaamas K
    Exp Oncol; 2018 Mar; 40(1):48-58. PubMed ID: 29600973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.
    Kodar K; Izotova J; Klaamas K; Sergeyev B; Järvekülg L; Kurtenkov O
    World J Gastroenterol; 2013 Jun; 19(23):3573-82. PubMed ID: 23801858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer.
    Kurtenkov O; Innos K; Sergejev B; Klaamas K
    Biomed Res Int; 2018; 2018():9579828. PubMed ID: 30105268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer.
    Kurtenkov O; Klaamas K
    Dis Markers; 2015; 2015():761908. PubMed ID: 26663951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential.
    Kurtenkov O; Izotova J; Klaamas K; Sergeyev B
    Biomed Res Int; 2014; 2014():830847. PubMed ID: 25276822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.
    Kurtenkov O; Klaamas K
    Biomed Res Int; 2017; 2017():6097647. PubMed ID: 28316982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Thomsen-Friedenreich antigen and alphaGal-specific human IgG glycoforms: concanavalin A reactivity and relation to survival of cancer patients.
    Kodar K; Kurtenkov O; Klaamas K
    Immunol Invest; 2009; 38(8):704-17. PubMed ID: 19860583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients.
    Smorodin EP; Kurtenkov OA; Sergeyev BL; Kodar KE; Chuzmarov VI; Afanasyev VP
    World J Gastroenterol; 2008 Jul; 14(27):4352-8. PubMed ID: 18666325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
    MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
    J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.
    Kurtenkov O; Klaamas K; Mensdorff-Pouilly S; Miljukhina L; Shljapnikova L; Chuzmarov V
    Acta Oncol; 2007; 46(3):316-23. PubMed ID: 17450466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
    Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin.
    Campbell BJ; Finnie IA; Hounsell EF; Rhodes JM
    J Clin Invest; 1995 Feb; 95(2):571-6. PubMed ID: 7860740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients.
    Smorodin E; Sergeyev B; Klaamas K; Chuzmarov V; Kurtenkov O
    Int J Med Sci; 2013; 10(12):1674-82. PubMed ID: 24151439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival.
    Kurtenkov O; Klaamas K; Rittenhouse-Olson K; Vahter L; Sergejev B; Miljukhina L; Shljapnikova L
    Exp Oncol; 2005 Jun; 27(2):136-40. PubMed ID: 15995632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.
    Kurtenkov O
    Biomed Res Int; 2020; 2020():9747040. PubMed ID: 32280709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of proliferation in human colon cancer cells by human monoclonal antibodies against the TF antigen (galactose beta1-3 N-acetyl-galactosamine).
    Yu LG; Jansson B; Fernig DG; Milton JD; Smith JA; Gerasimenko OV; Jones M; Rhodes JM
    Int J Cancer; 1997 Nov; 73(3):424-31. PubMed ID: 9359491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44.
    Singh R; Campbell BJ; Yu LG; Fernig DG; Milton JD; Goodlad RA; FitzGerald AJ; Rhodes JM
    Glycobiology; 2001 Jul; 11(7):587-92. PubMed ID: 11447138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
    Heublein S; Egger M; Zhu J; Berger L; Mayr D; Schindlbeck C; Kuhn C; Hofmann SS; Schuetz F; Jeschke U; Ditsch N
    Breast Cancer Res Treat; 2020 Feb; 179(3):643-652. PubMed ID: 31828591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cluster binding studies with two anti-Thomsen-Friedenreich (anti-core-1, CD176, TF) antibodies: Evidence for a multiple TF epitope.
    Flechner A; Butschak G; Löffler A; Rühmann J; Nishimura SI; Dölling R; Purfürst B; Goletz S; Danielczyk A; Karsten U
    Int Immunopharmacol; 2019 Jul; 72():186-194. PubMed ID: 30999209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The level of IgG antibodies reactive to TF, Tn and alpha-Gal polyacrylamide-glycoconjugates in breast cancer patients: relation to survival.
    Smorodin EP; Sergeyev BL
    Exp Oncol; 2016 Jun; 38(2):117-21. PubMed ID: 27356581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.